ORAGENICS INC
Close on Oct 19, 2026
- Market cap
- $1.87M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Oragenics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Oragenics filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
Listing notice · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Other events · EX-99.1 to Form 8-K
Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Other events · EX-99.1 to Form 8-K
EXPLORES EXPANSION OF CNS PLATFORM
Other events · EX-99.2 to Form 8-K
INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
on Solid Ground: From Vision to Execution
Other events · EX-99.1 to Form 8-K
Regains Full NYSE American Compliance,
Material agreement · Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Brain-First Recovery Platform Toward Clinical Milestones
Other events · EX-99.1 to Form 8-K
Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Completes Approximately $16.5 Million Offering
Material agreement · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Inc. Announces One-for-Thirty Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
Other events · EX-99.1 to Form 8-K
Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Other events · EX-99.1 to Form 8-K
Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Other events · EX-99.1 to Form 8-K
Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg
Other events · EX-99.1 to Form 8-K
Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO
Other events · EX-99.1 to Form 8-K
Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Other events · EX-99.1 to Form 8-K
Inc. Announces Pricing of Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Announces Closing of Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Listing notice · Other events · EX-99.1 to Form 8-K
Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Other events · EX-99.1 to Form 8-K
Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Other events · EX-99.1 to Form 8-K
Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Other events · EX-99.1 to Form 8-K
Improves Intranasal Drug Formulation for Treating Concussed Patients
Other events · EX-99.1 to Form 8-K
Inc. Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Announces Pricing of Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Inc. Announces Closing of Public Offering
Material agreement · Other events · EX-99.3 to Form 8-K
Appoints William “ Frank ” Peacock
Other events · EX-99.1 to Form 8-K